FDA OKs Gilead's oral hepatitis C drug sofosbuvir

12/8/2013 | Reuters · USA Today

The FDA has approved Sovaldi, or sofosbuvir, Gilead Sciences' drug for the treatment of chronic hepatitis C. The drug is taken once a day and is the first approved to treat hepatitis C infection without the need for interferon. It can be used in combination with ribavirin for those with genotypes 2 and 3 infections.

View Full Article in:

Reuters · USA Today

Published in Brief: